The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
The new functionality complements Parse’s existing Evercode immune products
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Subscribe To Our Newsletter & Stay Updated
